IS1609B - Hliðstæð aðferð til framleiðslu á benzofuran afleiðum og milliefni til notkunar við aðferðina - Google Patents

Hliðstæð aðferð til framleiðslu á benzofuran afleiðum og milliefni til notkunar við aðferðina

Info

Publication number
IS1609B
IS1609B IS3865A IS3865A IS1609B IS 1609 B IS1609 B IS 1609B IS 3865 A IS3865 A IS 3865A IS 3865 A IS3865 A IS 3865A IS 1609 B IS1609 B IS 1609B
Authority
IS
Iceland
Prior art keywords
intermediates
production
analogous method
benzofuran derivatives
benzofuran
Prior art date
Application number
IS3865A
Other languages
English (en)
Icelandic (is)
Other versions
IS3865A (is
Inventor
Clive Ross Barry
Middlemiss David
Ian Carter Scopes David
Iain Mclean Jack Torquil
Stuart Cardwell Kevin
Dennis Dowle Michael
Bruce Judd Duncan
Paul Watson Stephen
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of IS3865A publication Critical patent/IS3865A/is
Publication of IS1609B publication Critical patent/IS1609B/is

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS3865A 1991-05-16 1992-05-15 Hliðstæð aðferð til framleiðslu á benzofuran afleiðum og milliefni til notkunar við aðferðina IS1609B (is)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919110636A GB9110636D0 (en) 1991-05-16 1991-05-16 Chemical compounds

Publications (2)

Publication Number Publication Date
IS3865A IS3865A (is) 1992-11-17
IS1609B true IS1609B (is) 1996-10-18

Family

ID=10695121

Family Applications (1)

Application Number Title Priority Date Filing Date
IS3865A IS1609B (is) 1991-05-16 1992-05-15 Hliðstæð aðferð til framleiðslu á benzofuran afleiðum og milliefni til notkunar við aðferðina

Country Status (21)

Country Link
US (2) US5332831A (enExample)
EP (1) EP0514198B1 (enExample)
JP (1) JPH06211846A (enExample)
KR (1) KR920021541A (enExample)
AP (1) AP318A (enExample)
AT (1) ATE169297T1 (enExample)
AU (2) AU1692692A (enExample)
BG (1) BG98216A (enExample)
CA (1) CA2068766A1 (enExample)
CZ (1) CZ243093A3 (enExample)
DE (1) DE69226472D1 (enExample)
FI (1) FI935036A7 (enExample)
GB (1) GB9110636D0 (enExample)
IL (1) IL101882A0 (enExample)
IS (1) IS1609B (enExample)
MX (1) MX9202281A (enExample)
NO (1) NO921944L (enExample)
OA (1) OA09841A (enExample)
SK (1) SK112893A3 (enExample)
TW (1) TW221998B (enExample)
WO (1) WO1992020674A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9218449D0 (en) 1992-08-29 1992-10-14 Boots Co Plc Therapeutic agents
US5336779A (en) * 1992-10-08 1994-08-09 Nippon Gohsei Kagaku Kogyo Kabushiki Kaisha Method of producing formylimidazoles
DK0853477T3 (da) * 1995-10-06 2003-02-10 Novartis Ag AT1-receptor-antagonister til forebyggelse og behandling af postiskæmisk nyresvigt og til beskyttelse af iskæmiske nyrer
JP4369994B2 (ja) 1996-02-29 2009-11-25 ノバルティス アクチエンゲゼルシャフト アポトーシスの刺激のためのat▲下1▼レセプターアンタゴニスト
KR100567183B1 (ko) * 1997-11-14 2006-06-13 론자 아게 포르밀이미다졸의제조방법
US6465502B1 (en) 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
RU2271809C2 (ru) 1998-12-23 2006-03-20 Новартис Аг Применение антагониста рецептора at-1 или модулятора рецептора ат-2 для лечения болезней, связанных с увеличением содержания рецепторов ат-1 или ат-2
CN101011390A (zh) 1999-01-26 2007-08-08 诺瓦提斯公司 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
US6211217B1 (en) 1999-03-16 2001-04-03 Novartis Ag Method for reducing pericardial fibrosis and adhesion formation
DE60037192T2 (de) * 1999-07-21 2008-05-15 Takeda Pharmaceutical Co. Ltd. Mittel zur verbesserung der erkrankungen nach zerebralen durchblutungsstörungen sowie zur verhinderung deren fortschreitens
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
US6794405B2 (en) * 2000-08-17 2004-09-21 Merck & Co., Inc. Alicyclic imidazoles as H3 agents
DE10335027A1 (de) 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
ES2560247T3 (es) * 2006-05-05 2016-02-18 Dow Global Technologies Llc Complejos de hafnio de ligandos orgánicos heterocíclicos
AU2007292155B2 (en) 2006-09-05 2012-11-01 Kyowa Kirin Co., Ltd. Imidazole derivative
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
JP5072675B2 (ja) 2007-04-03 2012-11-14 四国化成工業株式会社 2−ハロイミダゾール化合物の製造方法
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2328910B1 (en) 2008-06-04 2014-08-06 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
HK1220611A1 (zh) 2013-03-15 2017-05-12 Bausch Health Ireland Limited 用於治疗胃肠道病症的组成物
CN113388007A (zh) 2013-06-05 2021-09-14 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
SI3648761T1 (sl) 2017-07-07 2024-07-31 Boehringer Ingelheim Vetmedica Gmbh Telmisartan za profilakso ali zdravljenje hipertenzije pri mačkah
CN110256382A (zh) * 2019-06-06 2019-09-20 武汉药明康德新药开发有限公司 一种2-(5-甲基苯并呋喃-2-基)苯甲腈的合成方法
CN121175053A (zh) 2023-05-24 2025-12-19 勃林格殷格翰动物保健有限公司 包含一或多种sglt-2抑制剂及替米沙坦的非人类哺乳动物中肾脏疾病和/或高血压的组合治疗和/或预防
WO2025125409A1 (en) 2023-12-15 2025-06-19 Boehringer Ingelheim Vetmedica Gmbh Angiotensin ii receptor antagonist for the prevention of systemic diseases in cats

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1389827A (en) * 1971-07-23 1975-04-09 Fisons Ltd Tetrazolyl benzopyrans
JPS54148788A (en) * 1978-05-15 1979-11-21 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative and its preparation
US4526896A (en) * 1978-12-26 1985-07-02 Riker Laboratories, Inc. Tetrazol-5-yl 2-nitro-3-phenylbenzofurans and antimicrobial use thereof
JPS5671073A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd Imidazole derivative
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
ZA824343B (en) * 1981-07-01 1983-04-27 Upjohn Co Pyridinyl- and imidazolyl-benzofurane and benzothiophenes
JPS6163671A (ja) * 1984-09-05 1986-04-01 Shionogi & Co Ltd 2,3−ジヒドロベンゾフラン−5−スルホンアミド誘導体および降圧利尿剤
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US4916129A (en) * 1989-01-19 1990-04-10 E. I. Du Pont De Nemours And Company Combination β-blocking/angiotensin II blocking antihypertensives
EP0403159B1 (en) * 1989-06-14 2000-03-01 Smithkline Beecham Corporation Imidazolyl-alkenoic acids
WO1991000277A1 (en) * 1989-06-30 1991-01-10 E.I. Du Pont De Nemours And Company Substituted imidazoles
KR950009860B1 (ko) * 1989-06-30 1995-08-29 이. 아이. 듀퐁 드 네모아 앤드 캄파니 융합된 환 아릴 치환된 이미다졸과 약제학적으로 허용되는 이의 염, 이들의 제조방법 및 이들을 함유하는 약제학적 조성물
JPH03204875A (ja) * 1989-10-03 1991-09-06 Wakamoto Pharmaceut Co Ltd テトラゾール酢酸誘導体、及び該誘導体を有効成分とするアルドースレダクターゼ阻害剤
CA2027937A1 (en) * 1989-10-25 1991-04-26 Richard M. Keenan Substituted 5-¬ (tetrazolyl)alkenyl|imidazoles
CA2028925A1 (en) * 1989-11-06 1991-05-07 Gerald R. Girard Substituted n-(imidazolyl)alkyl alanine derivatives
GB8927277D0 (en) * 1989-12-01 1990-01-31 Glaxo Group Ltd Chemical compounds
US5190942A (en) * 1991-04-22 1993-03-02 E. R. Squibb & Sons, Inc. Benzoxazole and related heterocyclic substituted imidazole and benzimidazole derivatives
IL101888A0 (en) * 1991-05-16 1992-12-30 Glaxo Group Ltd Benzofuran derivatives,their preparation and pharmaceutical compositions containing them
DE4140519A1 (de) * 1991-12-09 1993-06-17 Merck Patent Gmbh Benzofurane

Also Published As

Publication number Publication date
CA2068766A1 (en) 1992-11-17
EP0514198A1 (en) 1992-11-19
NO921944D0 (no) 1992-05-15
EP0514198B1 (en) 1998-08-05
US5332831A (en) 1994-07-26
TW221998B (enExample) 1994-04-01
FI935036A0 (fi) 1993-11-15
BG98216A (en) 1994-08-15
FI935036A7 (fi) 1993-11-15
NO921944L (no) 1992-11-17
GB9110636D0 (en) 1991-07-03
JPH06211846A (ja) 1994-08-02
DE69226472D1 (de) 1998-09-10
AU654350B2 (en) 1994-11-03
WO1992020674A1 (en) 1992-11-26
AP318A (en) 1994-02-15
MX9202281A (es) 1992-11-01
IL101882A0 (en) 1992-12-30
SK112893A3 (en) 1994-11-09
AU1692692A (en) 1992-12-30
ATE169297T1 (de) 1998-08-15
OA09841A (en) 1994-08-15
IS3865A (is) 1992-11-17
KR920021541A (ko) 1992-12-18
AU1632192A (en) 1993-03-11
US5498722A (en) 1996-03-12
CZ243093A3 (en) 1994-03-16

Similar Documents

Publication Publication Date Title
IS1609B (is) Hliðstæð aðferð til framleiðslu á benzofuran afleiðum og milliefni til notkunar við aðferðina
IS1713B (is) Hliðstæð aðferð til framleiðslu á andróstenón afleiðu og milliefni til notkunar með aðferðinni
IS4201A (is) Aðferð til framleiðslu á Benzofuran afleiðum
IS1618B (is) Aðferð til framleiðslu á benzanilíð afleiðum
IS3914A (is) Aðferð til framleiðslu á benzanilíð afleiðum
IS3994A (is) Hliðstæð aðferð til framleiðslu á indole afleiðum
IS3873A (is) Hliðstæð aðferð til framleiðslu á kristölluðum oxaþíólan afleiðum
DK451187A (da) Fremgangsmaade og apparat til kraftproduktion
NO177084C (no) Fremgangsmåte og anordning for kontinuerlig fremstilling av absorbente legemer
NO305634B1 (no) FremgangsmÕte og anordning for kake-produksjon
IS1708B (is) Hliðstæð aðferð til framleiðslu á vatnsuppleysanlegum kamptóþesín afleiðum
IS3823A (is) Ný carboxyl-amid efnasambönd og aðferð til framleiðslu þeirra
NO950412L (no) Fremgangsmåte og apparat for fremstilling av tremel, samt anvendelse derav til fremstilling av plater
IS3954A (is) Hliðstæð aðferð við framleiðslu nýrra peptíðafleiða
NO885006L (no) Fremgangsmaate og anordning for bevegelseskompensering av stigeroer.
NO176425C (no) Fremgangsmåte og anordning til kontinuerlig utglödning av amorfe bånd i produksjonslinjen
IS4012A (is) Tæki til að framleiða vinnslumiðil fyrir orkuver,einkum raforkuver, og aðferð til framleiðslu á áðurnefndum vinnslumiðli
IS4244A (is) Aðferð til framleiðslu á Indoline afleiðum og notkun þeirra
IS3792A7 (is) Benzodiazepinones og aðferð til framleiðslu þess
IS3555A7 (is) Pyrrol-afleiður og aðferð til framleiðslu þeirra
IS3857A (is) Karboxýl-sýruafleiður og aðferð til framleiðslu þeirra
DK0635004T3 (da) 4-Diphenylmethylpiperidinderivater og fremgangsmåde til fremstilling deraf
IS3969A (is) Hliðstæðar aðferðir til framleiðslu á bensópýran og skyldum LTB4 mótlyfjum
IS3827A (is) Hliðstæð aðferð við framleiðslu á pýrról[2,3 b]pýridínum
IS4980A (is) Aðferðir og milliefni við framleiðslu á setnum krómanól afleiðum